Global Diffuse Large B-cell Lymphoma Therapeutics Market

Table of Content

1. Introduction
   • Definition of Diffuse Large B-cell Lymphoma Therapeutics Market
   • Scope of the Report
2. Methodology
   • Executive Summary
   • Market Overview
   • Market Definition and Segmentation
3. Market Dynamics
   • Drivers
   • Restraints
   • Opportunities
   • Porter's Five Forces Analysis
   • PESTEL Analysis
4. Diffuse Large B-cell Lymphoma Therapeutics Market, By Drug Type
   • Immuno and Targeted Drugs
     • Rituximab (Rituxan)
     • Polatuzumabvedotin-piiq (Polivy)
     • Tisagenlecleucel (Kymriah)
     • Tafasitamab-cxix (Monjuvi)
     • Selinexor (XPOVIO)
     • Axicabtageneciloleucel (Yescarta)
     • Others (Pembrolizumab (Keytruda), Ibrutinib)
   • Others-Combination Drugs
5. Diffuse Large B-cell Lymphoma Therapeutics Market, By Route of Administration
   • Intravenous Route
   • Oral
   • Diffuse Large B-cell Lymphoma Therapeutics Market, By End-user
   • Hospitals
   • Cancer Centers
   • Others
6. Diffuse Large B-cell Lymphoma Therapeutics Market, By Geography
   • North America
     • United States
     • Canada
   • Europe
     • United Kingdom
     • Germany
     • France
     • Spain
     • Italy
     • Rest of Europe
   • Asia-Pacific
     • China
     • Japan
     • India
     • South Korea
     • Australia
     • Rest of Asia-Pacific
   • Latin America
     • Brazil
     • Mexico
     • Rest of Latin America
   • Middle East & Africa
     • Saudi Arabia
     • United Arab Emirates
     • South Africa
     • Rest of Middle East & Africa
7. Competitive Landscape
8. Company Profiles
   • F. Hoffmann-La Roche Ltd
     • Company Overview
     • Product Portfolio and Description
     • Key Highlights
     • Financial Overview
   • Novartis AG
   • Celltrion
   • Karyopharm Therapeutics
   • Kite Pharma
   • MorphoSys AG
   • AbbVie
   • CTI BioPharma
   • Seagen Inc
   • TG Therapeutics
9. Conclusion and Future Outlook
10. Appendix
    • Research Methodology
    • About the Pharmanucleus

11. Disclaimer